Global Anemia Drugs Market Size, Share, Forecast Report, 2020-2027

Anemia is a set of conditions characterized by weakness, shortness of breath and a general tiredness due to a decrease in the total amount of red blood cells (RBCs) or hemoglobin in the blood. The lowered hemoglobin results in a lowered ability of the blood to carry oxygen. There are three main types of anemia, i.e. due to blood loss, due to decreased or faulty red blood cell production and due to increased red blood cell breakdown. Anemia affects a quarter of people of the world and of the different types of anemia iron deficiency anemia comprises of the largest number of people affected, about 1 billion and resulting in approximately 215,000 deaths each year. Anemia is also more common in females than males. It also has a greater propensity to affect children, pregnant and lactating women and the elderly.

The global market for anemia drugs is growing at a good rate. The market driving factors are growth of geriatric population, increasing awareness, increasing focus of social healthcare on women health and particularly anemia, rise in accidents and cancer, rise in other risk factors such as diabetes, modern lifestyle induced stress, poor nutritional habits, rise in lactating and pregnant women in developing regions, intestinal infections etc.

The market constraints are poor absorption of drugs especially intravenous iron and the side effects associated with the treatment. Better nutrition due to rising per capita income is also a market limiting factor for anemic drugs.

The global market for Anemia Drugs is expected to be around US$21.4 billion and is expected to grow at a CAGR of 8.4% to reach US$34.7 billion by the end of forecast period.
Key Players for Global Anemia Drugs Market:

Some of the key players in this market are: Amgen Inc., GlaxoSmithKline plc, Bluebird bio, Biocon, GlycoMimetics Inc., Regen biopharma Inc., Bayer AG, Acceleron Pharma, Eli Lilly and company and others.

Market Segments:

Global anemia drugs market has been segmented on the basis of anemia type which comprises iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia pernicious anemia and others. On the basis of route of administration; market is segmented into oral and injectable. On the basis of gender; market is segmented into male and female. On the basis of product type; market is segmented into biologics and non-biologics. On the basis of end users; market is segmented into hospitals, self-administered and others.